Molecular Determinants of Unexplained Stillbirth: Genetic, Immune-Mediated, and Pharmacogenomic Contributors
Cells · 28.07.2026 · 15 (15) · 1354
DOI: 10.3390/cells15151354 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.07.2026. Verfasst von Petra Priscakova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University Bratislava, Sasinkova 4, 81108 Bratislava, Slo…. Hauptthemen laut MEDLINE: Stillbirth, Pharmacogenetics. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia.
Abstract (Originalsprache)
Intrauterine fetal death, also termed stillbirth, remains a major clinical challenge, with a substantial proportion of cases unresolved despite standard postmortem evaluation, limiting effective risk stratification and prevention. This structured narrative review synthesizes evidence from genetic, immune-mediated, and pharmacogenetic studies to summarize possible contributors to stillbirth with potential application in precision-oriented diagnostics and prevention of unexplained stillbirth. Integration of cytogenetic and sequencing approaches enhances detection of clinically relevant abnormalities in previously unexplained cases, while exome sequencing reveals additional molecular diagnoses beyond conventional chromosomal analyses. Genetic contributors include chromosomal abnormalities and a wide spectrum of heterogeneous monogenic disorders affecting cardiac electrophysiology, neuromuscular function, metabolic homeostasis, and early developmental processes. Immune-mediated placental dysfunction, particularly obstetric antiphospholipid syndrome, emerges as a clinically actionable mechanism characterized by vascular and inflammatory injury and associated angiogenic imbalance. Emerging pharmacogenetic evidence indicates that genetic variability in drug metabolism and receptor signaling may influence therapeutic response in placenta-mediated complications. Collectively, these findings support an integrated, mechanism-based framework combining genomic, immune, and pharmacogenetic data with phenotypic characterization to advance etiologic resolution, improve recurrence risk assessment, and enable precision-based diagnostic and preventive strategies in stillbirth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University Bratislava, Sasinkova 4, 81108 Bratislava, Slovakia.
- Institute of Immunology, Faculty of Medicine, Comenius University Bratislava, Odborárske námestie 14, 81108 Bratislava, Slovakia.
ORCID-Profile: Petra Priscakova, Ivana Shawkatova, Vanda Repiska, Helena Gbelcova
Förderung
- EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia
Zitieren
APA
Priscakova, P., Gergely, L., Shawkatova, I., Milosovicova, L., Repiska, V., & Gbelcova, H. (2026). Molecular Determinants of Unexplained Stillbirth: Genetic, Immune-Mediated, and Pharmacogenomic Contributors. Cells, 15(15), 1354. https://doi.org/10.3390/cells15151354
Vancouver
Priscakova P, Gergely L, Shawkatova I, Milosovicova L, Repiska V, Gbelcova H. Molecular Determinants of Unexplained Stillbirth: Genetic, Immune-Mediated, and Pharmacogenomic Contributors. Cells. 2026;15(15):1354. doi:10.3390/cells15151354
BibTeX
@article{Priscakova2026,
author = {Priscakova, Petra and Gergely, Lajos and Shawkatova, Ivana and Milosovicova, Lubica and Repiska, Vanda and Gbelcova, Helena},
title = {Molecular Determinants of Unexplained Stillbirth: Genetic, Immune-Mediated, and Pharmacogenomic Contributors},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1354},
doi = {10.3390/cells15151354}
}
EUVIMED